NCT02312622 2023-12-12
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Stanford University
Phase 2 Completed
Clinical Trials
12 trialsNCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT05158491 2022-01-05
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
JenKem Technology Co., Ltd.
Phase 1/2 Unknown
NCT00598975 2021-07-12
NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
Nektar Therapeutics
Phase 2 Completed
NCT00856375 2021-07-12
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Nektar Therapeutics
Phase 2 Completed
NCT01457118 2021-07-12
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Nektar Therapeutics
Phase 2 Completed
NCT01492101 2021-06-01
BEACON
Nektar Therapeutics
Phase 3 Completed
NCT01773109 2020-04-03
Etirinotecan Pegol (NKTR-102) in NSCLC
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01876446 2020-03-17
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00802945 2018-07-09
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
Nektar Therapeutics
Phase 2 Completed
NCT01976143 2016-12-22
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
Nektar Therapeutics
Phase 1 Completed
NCT01663012 2016-02-24
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Stanford University
Phase 2 Completed